Sun Xinyu X - OmicsDI

Show results for

Unknown (11)
Proteomics (11)
Transcriptomics (1)
Metabolomics (1)

Organisms

Homo sapiens (4)
Mus musculus (4)
Rattus norvegicus (2)
Danio rerio (1)
Verticillium dahliae VdLs.17 (1)

Repository

iProX (9)
pride (2)
biostudies-arrayexpress (1)
MetaboLights (1)

Tissue

Cell culture (1)
Lung (1)

Technology Type

Mass Spectrometry (2)
Mass spectrometry assay (1)
Data-dependent acquisition (1)
Data-independent acquisition (1)
Shotgun proteomics (1)

Instrument Platform

Liquid Chromatography MS - negative - reverse-phase (1)
Liquid Chromatography MS - positive - reverse-phase (1)

Publication Date

2026 (4)
2025 (2)
2024 (2)
2021 (2)
2016 (1)
2023 (1)
2019 (1)

Metabolite Name

(+/-)-Ethylketocyclazocine (1)
(+/-)-Tryptophan (1)
(+/-)12,13-Dihome (1)
(+/-)13-Hpode (1)
(-)-Caryophyllene Oxide (1)
(-)-Epigallocatechin 3-Cinnamate (1)
(1-Methyl-2-Oxoquinolin-4-Yl) N,N-Dimethylcarbamate (1)
(1R)-1-Amino-2-Sulfanylethanesulfinic Acid (1)
(2R)-2-Acetamido-3-[[(2R)-2-Acetamido-2-Carboxyethyl]Disulfanyl]Propanoic Acid (1)
(2R)-2-Acetamido-5-Hydroxy-2-(Sulfanylmethyl)Pentanoic Acid (1)
(2S)-3-Methyl-2-Naphthalen-1-Yloxybutanoic Acid (1)
(2S,3S,4S,5R)-3,4,5-Trihydroxy-6-Pyren-1-Yloxyoxane-2-Carboxylic Acid (1)
(3Beta,22R,23R,24S)-3,22,23-Trihydroxystigmastan-6-One (1)
(3E,5E)-2-(4-Methoxy-4-Oxobutyl)Nona-3,5-Dienoic Acid (1)
(3R)-3-Hydroxy-N-[(3S)-2-Oxooxolan-3-Yl]Butanamide (1)
(4E,7E)-Dodeca-4,7-Dienedioic Acid (1)
(6E)-8-Hydroxygeraniol (1)
(7Z)-Tetradec-7-Enedioylcarnitine (1)
(8As)-7-(3-Phenylpropyl)Hexahydroimidazo[1,5-A]Pyrazin-3(2H)-One (1)
(E)-3,10-Dihydroxy-12-Methoxy-4,9-Dimethyl-12-Oxododec-6-Enoic Acid (1)
(E)-4-[(1-Methoxy-1-Oxopropan-2-Yl)Amino]-4-Oxobut-2-Enoic Acid (1)
(R)-2-Hydroxysterculic Acid (1)
(R)-Canadine (1)
(R)-Heraclenol (1)
(S,E)-Zearalenone (1)
(Z)-2-(4-Methylpent-3-Enyl)-6-Oxohept-2-Enoic Acid (1)
(Z)-Resveratrol 3,4'-Diglucoside (1)
1,1,1-Trifluoroheptadecan-2-One (1)
1,10-Epoxy-3,8-Dihydroxy-4,11(13)-Germacradien-12,6-Olide (1)
1,2-Diferuloylgentiobiose (1)

Study type

MicroRNA profiling by array (1)

Release Date

2023 (4)
2025 (3)
2020 (2)
2016 (1)
2024 (1)
2019 (1)

Lab affiliation

MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou, China (1)
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China; The First Affiliated Hospital of Harbin Medical University (1)

Previous page
1 / 3
You're on page 1
page 2
page 3
Next page

Sort by:

Relevance

Page size

GMPS promoting tumor immune evasion by regulating the glycosylation modification of PD-L1

Hepatocellular carcinoma (HCC) is a malignant tumor characterized by rapid progression, whose development is attributed to severe immune evasion. Here, we conducted proteomic and scRNA-Seq analysis on advanced HCC tissues and identified a significant molecule, Guanine monophosphate synthase (GMPS). ...

ORGANISM(S): Mus musculus (Mouse)

2026-05-25 | PXD045485 | Pride

Visible-light-induced aerobic C3-H fluoroalkoxylation of quinoxalin-2(1H)-ones with fluoroalkyl alcohols.

Not available

S-EPMC9047172 | biostudies-literature

Combined transcriptomics and proteomics forecast analysis for potential biomarker in the acute phase of temporal lobe epilepsy.

Not available

S-EPMC10097945 | biostudies-literature

Screening and characterization of a novel linear B-cell epitope on orf virus F1L protein.

Not available

S-EPMC11224485 | biostudies-literature

Omics Analysis of Lung Adenocarcinoma with KRAS G12 Mutations

We conducted a proteomic analysis of LUAD patients with KRAS G12 mutations, and explore the interactome of KRAS G12 proteins. In conclusion, the findings of this study provide a deep understanding of the molecular mechanism of KRAS G12 mutation-driven LUAD.

ORGANISM(S): Homo sapiens (Human)

2026-06-08 | PXD058891 | Pride

Kras luad immune omics

A ferroptosis-related prognostic model with excellent clinical performance based on the exploration of the mechanism of oral squamous cell carcinoma progression.

Not available

S-EPMC9880000 | biostudies-literature

Efficacy and safety of Hou Gu Mi Xi for peptic ulcer diseases: Study protocol for a randomized controlled trial.

Not available

S-EPMC6709288 | biostudies-literature

Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial.

Not available

S-EPMC10563289 | biostudies-literature